Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Stem Cells

Julian Hitchcock's Biography



Julian Hitchcock, Counsel, Lawford Davies Denoon

Julian Hitchcock has advised life sciences clients since his admission as a solicitor in 1998. His legal career follows an education in medicine at the University of Birmingham and a number of years working at the BBC.

Julian has a particular focus on intellectual property and regulation. His deep involvement in the life science sector gives him a unique grasp of the sector's technologies and commercial imperatives. He provides commercially-oriented legal advice on contentious and non-contentious matters concerning medicinal products (pharmaceutical, immunological, biological, genetic or cellular), medical devices, stem cells, IVF, and genomic technologies. His views on regulation were widely cited in the recent House of Lords Science and Technology Committee's Regenerative Medicine Report.

Julian was previously Executive Director of the East of England Stem Cell Network, intellectual property representative on the UK National Stem Cell Network's commercialisation committee, an Associate of the PHG Foundation, a Research Fellow with the Global Biopolitics Research Group at King's College, London and founder of the CellFate regenerative medicine translation network. He has a long and close association with the Judge Business School and Bioscience Enterprise course at the University of Cambridge, lecturing on regenerative medicine and intellectual property law, mentoring MBA students, and co-founding a summer school in life science enterprise. In 2012, he was was appointed as a member of the Emerging Science and Bioethics Advisory Committee (ESBAC), the main UK advisory body on the wider implications of developments in bioscience and its impact for health, which is sponsored by the Chief Scientific Advisor for the Department of Health, England and which advises UK Health Departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications.

Julian Hitchcock Image

An Overview of the Regulatory Landscape Relevant to Tissue and Cell Based Therapies within the EU, considering both Adult and Embryonic Stem Cells

Thursday, 28 June 2012 at 14:45

Add to Calendar ▼2012-06-28 14:45:002012-06-28 15:45:00Europe/LondonAn Overview of the Regulatory Landscape Relevant to Tissue and Cell Based Therapies within the EU, considering both Adult and Embryonic Stem CellsSELECTBIOenquiries@selectbiosciences.com

Regulation is cited as the biggest obstacle to investment in regenerative medicine and stem cell science. In this talk, Julian Hitchcock sets out the European legal framework standing between research output and clinical implementation, highlighting some topical issues on the way.


Add to Calendar ▼2012-06-27 00:00:002012-06-28 00:00:00Europe/LondonStem CellsSELECTBIOenquiries@selectbiosciences.com